NFCR
Inhibox and the National Foundation for Cancer Research have worked together
since InhibOx's formation. The NFCR is one of the leading cancer charities in the USA.
It supports fundamental scientific research into cancer at nine NFCR research centres
around the world (including the NFCR centre for computational drug design at Oxford) as well
as providing funding to a large number of leading academics independent of these research centres.
InhibOx and NFCR have both participated in the "cancer screensaver project", a public
interest project based on utilising the idle time of over 3 million PC's around the world to
computationally screen 3.5 billion molecules against 12 cancer targets.
TopoTarget
TopoTarget is a fully integrated biopharmaceutical company whose objective is to find
"Answers for cancer" and develop and market novel anti-cancer therapeutics and to identify
new cancer indications for existing compounds. TopoTarget has built up a formidable development
pipeline based on key cancer enzyme regulators, mainly around the HDAC target
(inhibitors in multiple clinical trials) and topoisomerase II. The company is currently seeking
regulatory approval for its most advanced drug, Savene, an extravasation treatment. TopoTarget
has its HQ in Denmark with facilities also in the UK and Germany. The company is listed on the
Copenhagen stock exchange (CSE:TOPO).
ReOx
ReOx is a drug discovery company focused on developing novel treatments for disease by controlling
the activity of 2-oxoglutarate dependent oxygenases. ReOx was spun out from the University of Oxford
in 2003, by the founding scientists who have led the field of oxygen sensing for more than a decade.
Its world leading expertise and resultant exceptional intellectual property position places the company
at the forefront of one of today's most competitive areas of scientific activity, with an
impact over a wide range of important diseases.
Key DP
Key DP is based in the Netherlands and is a private, independent company that believes in the importance
of establishing the 3D structure of protein targets as the basis for rational drug design.
Key DP uses its high throughput protein crystallography capabilities in the provision of services
to the biotech and pharma industry, in joint discovery partnerships and in in-house programmes.
Surface Therapeutics
Surface Therapeutics Ltd is an Oxford University
spin-out that was founded in 2005 and which develops drugs and diagnostics for epitheal-related diseases.
The company is based on 20 years of world leading research from Professor William Cookson's laboratory
at the Wellcome Trust Centre for Human Genetics.
Phenex Pharmaceuticals
PheneX Pharmaceuticals AG , founded in 2002, is a biotechnology
company that focuses on the pharmalogically important drug target class of Nuclear Receptors. PheneX has developed
a unique research tool set for Nuclear receptor research and offer these technological assets to customers
interested in Nuclear Receptor research via the provision of drug discovery assets, services or integrated
drug discovery collaborations. In addition, PheneX itself pursues three proprietary discovery programs
focusing on the emerging drug targets LXR, FXR and ERR and those therapeutic applications where treatments are
unavailable or insufficient.
Latvian Institute of Organic Synthesis
LIOS is a prestigious research institute that was founded in 1957.
Its research focus is the investigation of biologically active substances and the development of drugs by the synthesis of new compounds.
More than 50 preparations have been created by the staff of the institute during the course of its work. 17 of these are original preparations
including the antitumour preparation Ftorafur (Tegafur), the antiflu preparation Remantadine, the immunomodulator Leakadine, the cardioprotector Mildronate,
Foridon a preparation for treating heart and vascular diseases, and the antioxidant Diludine.
